Independent regulatory and quality due diligence on medtech companies, and readiness assessments for your whole portfolio. In plain language, with the cost and time to close every gap.
Due diligence from €4,950 per company. Portfolio assessments from €950 per company.
Free · 20 minutes · no obligation. You leave with a clear first step.
Not sure who you need? Take the one-minute quiz
For VCs, angels and acquirers looking at a medtech company.
For incubators, accelerators and VCs with several medtech companies.
Twenty minutes to understand where you are and what you need.
A short proposal with the scope, the dates and a fixed price.
On site or remote, alongside your team, so nothing stops.
A clear report, a read-out, and the next steps in priority order.
Jasmine Beukema leads investor work. She spent close to twenty years in QA/RA leadership, including as VP QA/RA at Sophia Genetics and Vitestro, and steered the world's first fully autonomous robotic medical device through CE marking and FDA De Novo. She knows what a regulatory path costs, because she has walked it. Chani Galgut joins on quality systems and operations.
Yes. We sign your NDA before we see anything, and the report goes only to you.
With your permission, yes. A short interview with the founders and their quality lead usually tells us more than the documents alone.
Yes. We have no stake in the companies we assess, and we tell you up front if we have ever worked with one of them.
We time the work to your deal. Tell us the date on the first call and we scope to it.
Book a free call. You leave with a clear first step, whether or not you work with us.